Pelareorep receives FDA Fast Track for 2L KRAS‑mutant MSS metastatic colorectal cancer.
The FDA granted Fast Track Designation to pelareorep, given with bevacizumab and FOLFIRI, for second‑line treatment of KRAS‑mutant, microsatellite‑stable metastatic colorectal cancer, and Oncolytics said it applied after focusing on gastrointestinal cancer and reviewing its colorectal data.
